Safety and effectiveness of selpercatinib in patients with <i>RET</i> fusion-positive non-small cell lung cancer in real-world clinical practice: a postmarketing study in Japan
Real-world data showed selpercatinib to be effective in patients with RET fusion-positive NSCLC in Japan, with a favorable safety profile and no new safety concerns.
Authors
- Satoshi Wakabayashi
- Kevin Y. Urayama (ORCID: https://orcid.org/0000-0002-1360-9531)
- Yucherng Chen (ORCID: https://orcid.org/0000-0002-2755-0147)
- Joji Mori (ORCID: https://orcid.org/0000-0002-6545-464X)
Institutions
- Eli Lilly (Japan) (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1093/jjco/hyaf220
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00